PRA Health Sciences’ Early Development Services (EDS) has established a team dedicated to early phase patient studies. Our Early Patient Solutions (EPS) group has a unique combination of scientific, medical, and operational capabilities that enable us to conduct studies in patients with renal impairment. PRA has the benefit of two Clinical Research Units (CRUs) to conduct these studies in addition to established long-term relationships with specialty sites. With over 50 studies performed in this special area, we know how to do the job and will do it with the same efficiency expected in a Phase I study. When you select PRA to conduct your renal impairment trial, you can expect a fit-for-purpose solution, dedicated and experienced staff, and the highest quality data.
Early Phase Patient Studies
We provide the infrastructure, technologies, and expertise required to execute early phase patient studies around the world. Today, there is an…
Human Abuse Potential and Liability (HAP)
We’ve successfully completed more Human Abuse Potential and Liability (HAP/HAL) protocols & published more HAP studies than any other CRO.
Chemical, Manufacturing, and Control Services (CMC)
Early drug development requires manufacturing of Investigational Medicinal Products (IMP) that comply with Good Manufacturing Practice (GMP) systems…